| Literature DB >> 35935488 |
Yang Yang1,2, Cecilia Laterza1,2, Hannah T Stuart1,2, Federica Michielin2,3, Onelia Gagliano1,2, Anna Urciuolo2,4,5, Nicola Elvassore1,2,3.
Abstract
The human developmental processes during the early post-implantation stage instruct the specification and organization of the lineage progenitors into a body plan. These processes, which include patterning, cell sorting, and establishment of the three germ layers, have been classically studied in non-human model organisms and only recently, through micropatterning technology, in a human-specific context. Micropatterning technology has unveiled mechanisms during patterning and germ layer specification; however, cell sorting and their segregation in specific germ layer combinations have not been investigated yet in a human-specific in vitro system. Here, we developed an in vitro model of human ectodermal patterning, in which human pluripotent stem cells (hPSCs) self-organize to form a radially regionalized neural and non-central nervous system (CNS) ectoderm. We showed that by using micropatterning technology and by modulating BMP and WNT signals, we can regulate the appearance and spatial distribution of the different ectodermal populations. This pre-patterned ectoderm can be used to investigate the cell sorting behavior of hPSC-derived meso-endoderm cells, with an endoderm that segregates from the neural ectoderm. Thus, the combination of micro-technology with germ layer cross-mixing enables the study of cell sorting of different germ layers in a human context.Entities:
Keywords: cell sorting; ectoderm; hPSC differentiation; human in vitro model; micropatterning
Year: 2022 PMID: 35935488 PMCID: PMC9354750 DOI: 10.3389/fbioe.2022.907159
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
FIGURE 1Micropatterning technology for human iPSC geometric confinement. (A) Schematic representation of the micropatterning strategy which includes step 1: glass coverslip surface functionalization; step 2: Poly-L-lysine and Matrigel surface coating; and step 3: single-cell seeding and micropatterned colony formation. (B) Brightfield images of three independent batches showing a reproducible yield in the number of well-formed micropatterns per coverslip (12 mm diameter) using human pluripotent stem cells (iPSCs). (C,D) Optimization of the Matrigel concentration and time of rock inhibitor withdrawal. Graph showing quantification of the number of well-organized micropatterned iPSC colonies during 5 days modifying Matrigel coating concentration (C) and the time of Rock inhibitor withdrawal (D). (E) Number of colonies with intact round geometry (red, named without imperfection) and with non-preserved geometrical integrity (black, named imperfect) during 5 days of differentiation by applying the established method (1% Matrigel coating, Rock inhibitor withdrawal at 240 min). Data derived from at least three independent experiments (three coverslips per experiment). Error bars represent the standard error. (F) Representative images of micropatterns after 1 (D1) or 3 (D3) days from seeding. Scale bar = 1 mm.
FIGURE 2Effect of BMP and WNT signaling on neural ectoderm patterning. (A–D) Representative images of micropatterns obtained inducing neural differentiation via exposure with APD mix (A83-01, PNU74654, and Dorsomorphin) in MEF-conditioned medium (MEF-CM) (protocol n2). Shown are immunostaining for the neural ectoderm NESTIN (green), PAX6 (purple), and SOX1 (light blue) (A), and neural crest markers AP2a (green) and p75 (red) (B) and nuclei are counterstained with Hoechst (blue). (C) Graph showing the spatial distribution of neural ectoderm markers (PAX6, SOX1, and NESTIN) and neural crest markers (AP2a) under geometric confinement expressed as average nuclear intensities of the indicated marker as a function of distance from the colony center. (D) Schematic representation of the distribution of neural ectodermal and neural crest populations within micropatterns. (E–H) Schematic representation of six different combinations of signaling molecules (TGFb inhibitors; BMP inhibitors; and WNT inhibitors) and basal media within 5 days of the experiment. (E,G) Representative images of neural patterned human iPSCs by applying different induction protocols on day 5 of culture. (F,H) Shown are Pax6 (red, neuroectoderm marker) and AP-2α (green, neural crest marker). Scale bar = 100 μm. The dashed white circles indicate the region of micropatterns. N> = 5. MEF-CM = MEF-conditioned media; LDN = LDN193189; SB = SB431542; APD = A83-01, PNU74654, and Dorsomorphin; Ri = Rock inhibitor.
FIGURE 3Spatial distribution of the meso-endoderm on different neuroectoderm micropatterns. (A) Schematic representation of the co-culture strategy of human iPSC micropatterned toward the neural ectoderm and human iPSC-derived GFP + meso-endoderm M-E. (B–D) Interaction between three extreme conditions of neuroectoderm micropatterning and GFP + meso-endoderm. Schematic representation of the different patterning conditions and time course from seeding to day 3 of co-culture. (B) In the n2 condition, which gives rise to the central NC population (AP2a-positive), the M-E is localized within and outside the PAX6-positive ring; (C) in the n4 condition, in which there is no PAX6-positive population at day 5 and the pattern is made of AP2a-positive cells, M-E spread on top of the patterns; (D) in n6 condition, in which there is only a PAX6-positive population and no AP2a, M-E localizes at the edge of the patterns. Pax6 (CNS marker) and AP-2α (NC marker, “+ +” represents relatively high expression and “+” represents relatively low expression). Scale bar = 100 μm N > = 5.
FIGURE 4Cell sorting of meso-endoderm cells on micropatterned ectoderm culture. Representative images of meso-endoderm at day 3 after seeding on ectoderm micropatterns stained for GFP (green) to visualize the meso-endoderm, SOX17 (red) to the mark endoderm, and Nestin (purple) to mark the neural ectoderm (A), or coupled with PAX6 (red) to mark the neural ectoderm and Brachyury (purple) to mark the mesoderm (B). Scale bar = 100 μm.
List of antibodies used.
| Name | Brand and code (cat. no.) |
|---|---|
| AP-2a (3B5) | Santa Cruz Biotechnology, cat. no. sc-12726 |
| Pax6 | BioLegend, cat. no. 901301/PRB-278P |
| Sox17 | R&D, cat. no. AF1924 |
| Brachyury | R&D, cat. no. AF2085 |
| Sox1 | R&D, cat. no. AF3369 |
| OCT4 | Santa Cruz Biotechnology, cat. no. sc-5279 |
| Sox2 | EMD Millipore, cat. no. AB5603 |
| Anti-p75 | Promega, cat. no. G323A |